AstraZeneca's potential coronavirus vaccine likely to provide protection for a year

On June 16, AstraZeneca's chief executive said that potential coronavirus vaccine is likely to provide protection against contracting COVID-19 for at least a year while speaking with state brocaster.  British drugmaker was alrey in human trials phase of vaccine developed by University of Oxford, with a phase I trial in Britain due to end soon and a phase III trial alrey begun, Pascal Soriot told brocaster Bel RTL.  

With a target of manufacturing up to 400 million doses of potential vaccine, AstraZeneca has signed contract with France, Germany, Italy, and Nerlands to supply European Union, as per reports. Soriot reportedly said that vaccine would protect against disease for a year. Furr, company plans to begin delivering vaccine to European countries by end of year 2020 under agreement with Inclusive Vaccine Alliance. Developed by Oxford University, cost of manufacturing vaccine is expected to be supported by UK government’s funding, following approval, AstraZeneca CEO Pascal Soriot said in a statement. 

Earlier, this month,  British drugmaker claimed that it secured a fresh deal with companies in United States to vance antibody-related coronavirus treatments. While pharma company did t reveal specific details about deal, reports suggest it has signed agreements with Biomedical vanced Research and Development Authority (BARDA) and Defense vanced Research Projects ncy (DARPA). new agreements would enable AstraZeneca to double its production from one billion doses to two billion doses.

Re: Oxford COVID-19 Trial Of HCQ To Continue Despite WHO's Temporary Suspension Of Drug

Re: Oxford's COVID-19 Vaccine Trial Has Only 50% Chance Of Success, Says Director

Vaccine for low- and middle-income countries

Furr, British company signed deals with Coalition for Epidemic Preparedness Invations (CEPI), Gavi Vaccine Alliance, and Serum Institute of India (SII), world's largest manufacturer of vaccines by volume, to bring vaccine to low- and middle-income countries to make  vaccine a “public good”.  AstraZeneca ‘s chief executive Pascal Aoriot while speaking to International media reporters said that need for a vaccine to defeat  COVID-19 pandemic was urgent. He ded that he hoped that by collaboration y could accelerate spre of vaccine and protect people from “deliest pandemic of generation” 

Re: Experts Warn COVID-19 Vaccines Might Be Ineffective, Come With 'limitation'

Re: France's Macron Visits Vaccine Research Centre

(Im Credit: Twitter/ @datagramtwo)